Trial Profile
An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2020
Price :
$35
*
At a glance
- Drugs Plecanatide (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors Synergy Pharmaceuticals Inc
- 05 Jun 2018 Results (n=2272) presented at the Digestive Disease Week 2018.
- 29 May 2018 According to the Synergy Pharmaceuticals Inc, data from this study will be presented at Digestive Disease Week 2018.
- 03 Oct 2017 Status changed from recruiting to completed.